Page last updated: 2024-11-04

danthron

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Danthron is a synthetic anthraquinone derivative with laxative properties. It is produced by the reduction of anthraquinone. Danthron is a prodrug that is metabolized in the gut to rhein, an active metabolite with laxative effects. Danthron is used to treat constipation and is also being studied for its potential use in treating inflammatory bowel disease and cancer. Research is ongoing to understand its potential therapeutic applications and any associated risks.'

danthron: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chrysazin : A dihydroxyanthraquinone that is anthracene-9,10-dione substituted by hydroxy groups at positions 1 and 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2950
CHEMBL ID53418
CHEBI ID3682
SCHEMBL ID83688
MeSH IDM0045328

Synonyms (182)

Synonym
BRD-K10065684-001-02-5
BRD-K10065684-001-03-3
wln: l c666 bv ivj dq nq
nsc7210 ,
anthraquinone,8-dihydroxy-
altan
usaf nd-59
component of doxan
nsc-7210
istizin
laxipurin
antrapurol
dantron
laxanthreen
component of dorbantyl
9, 1,8-dihydroxy-
zwitsalax
1,8-dihydroxyanthrachinon
diaquone
laxipur
dionone
dorbane
dorbanex
danivac
ltan
component of modane
laxanorm
component of doxidan
MLS000069608
smr000059018
nsc38626
nsc-38626
EU-0099935
KBIO1_000284
DIVK1C_000284
NCI60_041443
NCIMECH_000114
1,8-dihydroxyanthra-9,10-quinone
dioxyanthrachinonum
1,8-dihydroxy-9,10-anthracenedione
dantrone
CHEBI:3682 ,
1,8-dihydroxy-9,10-anthraquinone
dantrona
dantronum
nsc-646568
SPECTRUM_001750
SPECTRUM4_001682
BSPBIO_002259
9,10-anthracenedione, 1,8-dihydroxy-
pilules vinchy n.f. (tn)
dantron (inn)
D07107
ACON1_000135
SPECTRUM5_000324
IDI1_000284
MEGXP0_001693
1,8-dihydroanthraquinone
nsc646568
1,8-dihydroxyanthracene-9,10-dione
NCGC00091367-01
inchi=1/c14h8o4/c15-9-5-1-3-7-11(9)14(18)12-8(13(7)17)4-2-6-10(12)16/h1-6,15-16
duolax
dantronum [inn-latin]
roydan
bancon
nsc 646568
einecs 204-173-5
danthrone
dantrona [inn-spanish]
dantrone [inn-french]
1,4,5,8-tetroxyantraquinone
1,8-dihydroxyanthrachinon [czech]
ai3-38117
nsc 38626
ccris 3529
istan
prugol
scatron d
pastomin
neokutin s
anthraquinone, 1,8-dihydroxy-
1,8-dihydroxyanthraquinone
danthron
chrysazin
117-10-2
1,8-dihydroxyanthraquinone, 96%
DB04816
1,8-dihydroxy-9,10-dihydroanthracene-9,10-dione
1,8-dihydroxy-anthraquinone
bdbm11316
chembl53418 ,
NCGC00091367-02
KBIO2_007366
KBIO2_004798
KBIO3_001479
KBIOSS_002230
KBIOGR_001944
KBIO2_002230
SPECTRUM3_000650
SPBIO_000506
SPECTRUM2_000603
NINDS_000284
SPECTRUM211468
NCGC00091367-03
NCGC00091367-04
STK238373
HMS2091A09
istizine
D0563
chz ,
pilules vinchy n.f.
HMS500O06
A803710
1,8-bis(oxidanyl)anthracene-9,10-dione
AKOS001583216
NCGC00091367-07
NCGC00091367-05
NCGC00091367-06
unii-z4xe6ibf3v
hsdb 7764
z4xe6ibf3v ,
danthron [usp]
dantron [inn]
tox21_200986
NCGC00258539-01
BBL013161
nsc755828
pharmakon1600-00211468
nsc-755828
cas-117-10-2
tox21_111122
dtxsid9020328 ,
dtxcid10328
S4561
CCG-35470
criasazin
chrysazine
FT-0624445
danthron [mi]
danthron [hsdb]
dantron [iarc]
dantron [who-dd]
danthron [vandf]
dantron [mart.]
dithranol impurity b [ep impurity]
SCHEMBL83688
3NSQ
tox21_111122_1
HS-1003
CS-4392
1,8-dihydroxyanthra-9,10-quinone #
dorbanex (salt/mix)
dorbantyl (salt/mix)
W-108572
HY-B0923
AB00051961_09
mfcd00001211
sr-01000721864
SR-01000721864-2
1,8-dihydroxyanthraquinone, vetec(tm) reagent grade, 96%
1,8-dihydroxyanthracene-9,10-dione (danthron)
danthron (1,8-dihydroxyanthracene-9,10-dione)
laxapur
SBI-0051330.P003
HMS3715F08
dantron, inn
1,8-dihydroxy-9,10-anthracenedione, 9ci
danthron, ban
SY011288
8,9-dihydroxy-1,10-anthraquinone
Q5221244
dihyanthraquin_p41_lt
dihyanthraquin_p41212_rt
dihyanthraquin_p21/n_lt
F17670
1,8-dihydroxyanthraquinone ,(s)
AM10629
BRD-K10065684-001-06-6
BCP31079
dantron; chrysazin;1,8-dihydroxyanthraquinone;1,4,5,8-tetroxyantraquinone
EN300-1693514

Research Excerpts

Overview

Danthron is an important natural occurring component in laxative drugs.

ExcerptReferenceRelevance
"Danthron is an important natural occurring component in laxative drugs. "( Electrochemical studies of danthron and the DNA-danthron interaction.
Anzai, J; Hoshi, T; Kashiwagi, Y; Li, G; Sun, Z; Zhou, H, 2005
)
2.07

Effects

ExcerptReferenceRelevance
"Danthron has been shown to induce apoptotic cell death, and inhibit migration and invasion of human gastric or brain cancer cells in vitro. "( Danthron inhibits murine WEHI-3 cells in vivo, and enhances macrophage phagocytosis and natural killer cell cytotoxic activity in leukemic mice.
Chen, YL; Chiang, JH; Chiu, TH; Chung, JG; Hsueh, SC; Huang, AC; Hung, FM; Liu, CM; Lu, CC; Lu, HF; Yang, JS; Yu, CC,
)
3.02

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Rhein concentration time courses showed highest levels of 150-160 ng/ml and peak maxima at 3-5 h and 10-11 h after dosing probably according to absorption of free rhein and rhein released from prodrugs (e."( Rhein and aloe-emodin kinetics from senna laxatives in man.
Krumbiegel, G; Schulz, HU, 1993
)
0.29
" The net benefit from the glucose lowering effect and mixed type inhibition by emodin would enable the administration of a small dosage that is safe and non-toxic in the case of prolonged use in treating diabetes."( Evaluation of anti-diabetic and alpha glucosidase inhibitory action of anthraquinones from Rheum emodi.
Arvindekar, A; Ghoshal, N; Laddha, K; More, T; Payghan, PV, 2015
)
0.42
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
apoptosis inducerAny substance that induces the process of apoptosis (programmed cell death) in multi-celled organisms.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
dihydroxyanthraquinone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (56)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency20.00510.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency31.62280.004023.8416100.0000AID485290
Chain A, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency19.95260.025120.237639.8107AID893
interleukin 8Homo sapiens (human)Potency74.97800.047349.480674.9780AID651758
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
phosphopantetheinyl transferaseBacillus subtilisPotency28.18380.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency11.40490.006038.004119,952.5996AID1159521; AID1159523
SMAD family member 2Homo sapiens (human)Potency31.22100.173734.304761.8120AID1346859
SMAD family member 3Homo sapiens (human)Potency31.22100.173734.304761.8120AID1346859
GLI family zinc finger 3Homo sapiens (human)Potency0.10590.000714.592883.7951AID1259369
Microtubule-associated protein tauHomo sapiens (human)Potency8.11600.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency10.23970.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743036
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.99530.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency15.70560.000657.913322,387.1992AID1259377
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency40.11980.001022.650876.6163AID1224838; AID1224839; AID1224893
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency1.09640.01237.983543.2770AID1645841
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency21.22940.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency34.58140.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency3.93050.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency3.34910.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.49630.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743078; AID743079; AID743080; AID743091
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency7.94330.707936.904389.1251AID504333
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency44.66840.001024.504861.6448AID588535
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency23.51980.001019.414170.9645AID588536; AID743094; AID743191
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency5.74570.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency6.17530.001723.839378.1014AID743083
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.00170.057821.109761.2679AID1159526
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency35.48130.001815.663839.8107AID894
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency21.31450.354828.065989.1251AID504847
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.89130.010039.53711,122.0200AID588545
histone deacetylase 9 isoform 3Homo sapiens (human)Potency28.52540.037617.082361.1927AID1259364
huntingtin isoform 2Homo sapiens (human)Potency12.58930.000618.41981,122.0200AID1688
mitogen-activated protein kinase 1Homo sapiens (human)Potency15.15720.039816.784239.8107AID1454; AID995
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency27.76530.000627.21521,122.0200AID651741; AID720636; AID743202; AID743219
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency10.00000.00798.23321,122.0200AID2551
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
survival motor neuron protein isoform dHomo sapiens (human)Potency35.48130.125912.234435.4813AID1458
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency2.51190.00419.962528.1838AID2675
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
lamin isoform A-delta10Homo sapiens (human)Potency13.89140.891312.067628.1838AID1487
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency34.18520.001557.789015,848.9004AID1259244
Cellular tumor antigen p53Homo sapiens (human)Potency18.99950.002319.595674.0614AID651631; AID720552
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency34.18520.001551.739315,848.9004AID1259244
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Thioredoxin reductase 1, cytoplasmicRattus norvegicus (Norway rat)IC50 (µMol)200.00000.27201.82606.0000AID551520
TransthyretinHomo sapiens (human)IC50 (µMol)100.00000.16004.292110.0000AID1755162
Amine oxidase [flavin-containing] AHomo sapiens (human)IC50 (µMol)10.70000.00002.37899.7700AID1888748
Amine oxidase [flavin-containing] BHomo sapiens (human)IC50 (µMol)58.70000.00001.89149.5700AID1888749
Casein kinase II subunit alphaZea maysKi40.00001.85001.85001.8500AID1796663
Casein kinase II subunit alphaHomo sapiens (human)Ki40.00000.00041.09847.6700AID435887
5-lipoxygenase Bos taurus (cattle)IC50 (µMol)30.00000.18001.75824.0000AID160507
Sialidase-2Homo sapiens (human)IC50 (µMol)1,000.00003.90006.73337.8000AID466938
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain B, Retinoid X receptor, alphaHomo sapiens (human)Kd6.20006.20006.20006.2000AID977611
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (174)

Processvia Protein(s)Taxonomy
signal transductionTransthyretinHomo sapiens (human)
purine nucleobase metabolic processTransthyretinHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
biogenic amine metabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
positive regulation of signal transductionAmine oxidase [flavin-containing] AHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] AHomo sapiens (human)
response to xenobiotic stimulusAmine oxidase [flavin-containing] BHomo sapiens (human)
response to toxic substanceAmine oxidase [flavin-containing] BHomo sapiens (human)
response to aluminum ionAmine oxidase [flavin-containing] BHomo sapiens (human)
response to selenium ionAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of serotonin secretionAmine oxidase [flavin-containing] BHomo sapiens (human)
phenylethylamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
substantia nigra developmentAmine oxidase [flavin-containing] BHomo sapiens (human)
response to lipopolysaccharideAmine oxidase [flavin-containing] BHomo sapiens (human)
dopamine catabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to ethanolAmine oxidase [flavin-containing] BHomo sapiens (human)
positive regulation of dopamine metabolic processAmine oxidase [flavin-containing] BHomo sapiens (human)
hydrogen peroxide biosynthetic processAmine oxidase [flavin-containing] BHomo sapiens (human)
response to corticosteroneAmine oxidase [flavin-containing] BHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
double-strand break repairCasein kinase II subunit alphaHomo sapiens (human)
protein phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
DNA damage responseCasein kinase II subunit alphaHomo sapiens (human)
signal transductionCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell population proliferationCasein kinase II subunit alphaHomo sapiens (human)
Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of translationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-serine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
peptidyl-threonine phosphorylationCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of Wnt signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of cell growthCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of proteasomal ubiquitin-dependent protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of protein catabolic processCasein kinase II subunit alphaHomo sapiens (human)
rhythmic processCasein kinase II subunit alphaHomo sapiens (human)
protein stabilizationCasein kinase II subunit alphaHomo sapiens (human)
chaperone-mediated protein foldingCasein kinase II subunit alphaHomo sapiens (human)
symbiont-mediated disruption of host cell PML bodyCasein kinase II subunit alphaHomo sapiens (human)
positive regulation of aggrephagyCasein kinase II subunit alphaHomo sapiens (human)
regulation of chromosome separationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of double-strand break repair via homologous recombinationCasein kinase II subunit alphaHomo sapiens (human)
negative regulation of apoptotic signaling pathwayCasein kinase II subunit alphaHomo sapiens (human)
regulation of cell cycleCasein kinase II subunit alphaHomo sapiens (human)
glycoprotein catabolic processSialidase-2Homo sapiens (human)
ganglioside catabolic processSialidase-2Homo sapiens (human)
oligosaccharide catabolic processSialidase-2Homo sapiens (human)
glycosphingolipid catabolic processSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (54)

Processvia Protein(s)Taxonomy
hormone activityTransthyretinHomo sapiens (human)
protein bindingTransthyretinHomo sapiens (human)
identical protein bindingTransthyretinHomo sapiens (human)
thyroid hormone bindingTransthyretinHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] AHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] AHomo sapiens (human)
protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
primary amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
electron transfer activityAmine oxidase [flavin-containing] BHomo sapiens (human)
identical protein bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
aliphatic amine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
monoamine oxidase activityAmine oxidase [flavin-containing] BHomo sapiens (human)
flavin adenine dinucleotide bindingAmine oxidase [flavin-containing] BHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein serine/threonine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
protein bindingCasein kinase II subunit alphaHomo sapiens (human)
ATP bindingCasein kinase II subunit alphaHomo sapiens (human)
kinase activityCasein kinase II subunit alphaHomo sapiens (human)
identical protein bindingCasein kinase II subunit alphaHomo sapiens (human)
Hsp90 protein bindingCasein kinase II subunit alphaHomo sapiens (human)
protein serine kinase activityCasein kinase II subunit alphaHomo sapiens (human)
exo-alpha-sialidase activitySialidase-2Homo sapiens (human)
protein bindingSialidase-2Homo sapiens (human)
exo-alpha-(2->3)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->6)-sialidase activitySialidase-2Homo sapiens (human)
exo-alpha-(2->8)-sialidase activitySialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
extracellular regionTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
azurophil granule lumenTransthyretinHomo sapiens (human)
extracellular exosomeTransthyretinHomo sapiens (human)
extracellular spaceTransthyretinHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] AHomo sapiens (human)
cytosolAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] AHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial envelopeAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrial outer membraneAmine oxidase [flavin-containing] BHomo sapiens (human)
dendriteAmine oxidase [flavin-containing] BHomo sapiens (human)
neuronal cell bodyAmine oxidase [flavin-containing] BHomo sapiens (human)
mitochondrionAmine oxidase [flavin-containing] BHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
PcG protein complexCasein kinase II subunit alphaHomo sapiens (human)
PML bodyCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
nucleoplasmCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
plasma membraneCasein kinase II subunit alphaHomo sapiens (human)
protein kinase CK2 complexCasein kinase II subunit alphaHomo sapiens (human)
Sin3-type complexCasein kinase II subunit alphaHomo sapiens (human)
cytosolCasein kinase II subunit alphaHomo sapiens (human)
nucleusCasein kinase II subunit alphaHomo sapiens (human)
cytosolSialidase-2Homo sapiens (human)
catalytic complexSialidase-2Homo sapiens (human)
lysosomeSialidase-2Homo sapiens (human)
membraneSialidase-2Homo sapiens (human)
cytoplasmSialidase-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (155)

Assay IDTitleYearJournalArticle
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1336378Antagonist activity at SRA in RM1-OVA tumor bearing wild type C57BL/6 mouse derived CD11bpositiveLy6ChighLy6Gnegative myeloid-derived suppressive cells co-cultured with splenocytes assessed as reduction in protein-mediated inhibition of anti CD3/CD28 anti2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A.
AID336958Cytotoxicity against human Raji cells assessed as cell viability at 500 molar ratio
AID311299Antibacterial activity against Proteus vulgaris at pH 52007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID624612Specific activity of expressed human recombinant UGT1A92000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID683456Toxicity against human BxPC3 cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID1605075-LO inhibitory activity was determined by inhibition of LTB4 biosynthesis in bovine polymorphonuclear leukocytes (PMNL)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID19630Partition coefficient (logP)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID85489Induction of Keratinocyte Differentiation in cross-linked envelope assay at 1 uM expressed as difference of the amount of cross-linked protein as a measure of HaCaT keratinocyte differentiation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID551520Inhibition of rat liver cytosolic TrxR1 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID311296Antibacterial activity against Proteus mirabilis at pH 62007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID336957Cytotoxicity against human Raji cells assessed as cell viability at 1000 molar ratio
AID1148359Metal chelating activity of the compound assessed as metal-compound complex formation using Mn2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID102411Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 3 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID687633Binding affinity to calf thymus DNA at 50 uM by circular dichroism spectra2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID687632Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM by UV-vis spectroscopy in presence of denatured DNA2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID687631Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM by UV-vis spectroscopy in presence of native DNA2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID335924Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of collagen-stimulated platelet aggregation pretreated 2 mins before collagen challenge
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID336960Cytotoxicity against human Raji cells assessed as cell viability at 10 molar ratio
AID624613Specific activity of expressed human recombinant UGT1A102000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID85486Cytotoxic activity (2 uM) was measured by the amount of LDH (mU) release in HaCaT cells.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID85491Induction of Keratinocyte Differentiation in cross-linked envelope assay at 5 uM expressed as difference of the amount of cross-linked protein as a measure of HaCaT keratinocyte differentiation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID683448Toxicity against human MDA-M cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID1336375Antagonist activity at mouse recombinant SRA extracellular domain expressed in baculovirus infected Sf21 insect cells assessed as inhibition of protein-induced reduction of IL2 gene promoter activation in anti CD3/CD28 antibody activated wild type C57BL/62017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1148357Metal chelating activity of the compound assessed as metal-compound complex formation using copper1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID683454Toxicity against human MCF10A cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID687635Binding affinity to calf thymus DNA assessed as hydrogen bonding2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID311300Antibacterial activity against Proteus mirabilis at pH 52007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID102409Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 1 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID311290Antibacterial activity against Escherichia coli at pH 72007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID311297Antibacterial activity against Pseudomonas aeruginosa at pH 62007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID231071Peroxidant property was expressed as ratio of uMol of malondialdehyde and mMol of deoxyribose released by 75 uM test compound1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID336959Cytotoxicity against human Raji cells assessed as cell viability at 100 molar ratio
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID687629Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM at pH 7 by by UV-vis spectroscopy2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID285172Effect on Streptococcus mutans LMG 14558 assessed as inhibition of biofilm formation in modified Robbin's device at 5 ug/ml relative to BHIS control2007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1148360Metal chelating activity of the compound assessed as metal-compound complex formation using Ca2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID1888749Inhibition of recombinant human MAO-B expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID336956Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 10 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID683450Antimalarial activity against chloroquine-sensitive Plasmodium falciparum 3D7 assessed as reduction in parasite replication at 40 uM incubated for 62 hrs2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID1148364Metal chelating activity of the compound assessed as stability constant of metal chelate at 1 to 4.5 x 10'-5 M using Zn2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID683457Toxicity against human SU8686 cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID336953Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 1000 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1888748Inhibition of recombinant human MAO-A expressed in baculovirus infected BTI insect cells using kynuramine as substrate after 20 mins by fluorescence spectrophotometric assay2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID466938Inhibition of human Neu2 assessed as MuNANA substrate hydrolysis in presence of 0.1% Triton X-100 by discontinuous fluorimetric assay2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID311292Antibacterial activity against Proteus mirabilis at pH 72007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID336954Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 500 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID1888750Selectivity index, ratio IC50 for recombinant human MAO-B to IC50 for recombinant human MAO-A2022Bioorganic & medicinal chemistry, 01-15, Volume: 54Phenothiazine, anthraquinone and related tricyclic derivatives as inhibitors of monoamine oxidase.
AID624609Specific activity of expressed human recombinant UGT1A62000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID683451Antimalarial activity against chloroquine-resistant Plasmodium falciparum Dd2 assessed as reduction in parasite replication at 40 uM incubated for 62 hrs2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID85493Compound was tested for the induction of HaCaT keratinocyte differentiation at 1 uM expressed as the amount of cross-linked protein in cornified envelope assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID687628Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM at pH 7 in presence of NaCl by UV-vis spectroscopy2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1148361Metal chelating activity of the compound assessed as metal-compound complex formation using Mg2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID551521Inhibition of rat liver mitochondrial TrxR2 by spectrophotometry2011Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1
Hypericins and thioredoxin reductase: Biochemical and docking studies disclose the molecular basis for effective inhibition by naphthodianthrones.
AID1148366Metal chelating activity of the compound assessed as stability constant of metal chelate at 1 to 4.5 x 10'-5 M using Mn2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID683455Toxicity against human BT474 cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID233179Antioxidant potential was assessed from reducing activity against 2,2,di-phenyl-1-picrylhydrazyl.1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID85494Compound was tested for the induction of HaCaT keratinocyte differentiation at 10 uM expressed as the amount of cross-linked protein in cornified envelope assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID336955Inhibition of TPA-induced EBV-early antigen activation in human Raji cells at 100 molar ratio after 48 hrs by indirect immunofluorescence technique relative to TPA
AID683595Antitrypanosomal activity against Trypanosoma brucei brucei up to 40 uM incubated for 48 hrs by Alamar Blue assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID683447Toxicity against human PANC1 cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID85482Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)1997Journal of medicinal chemistry, Nov-07, Volume: 40, Issue:23
Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity.
AID624610Specific activity of expressed human recombinant UGT1A72000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID311295Antibacterial activity against Proteus vulgaris at pH 62007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID311301Antibacterial activity against Pseudomonas aeruginosa at pH 52007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID1148370Metal chelating activity of the compound assessed as stability constant of metal chelate at 1 to 4.5 x 10'-5 M using Ca2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID311293Antibacterial activity against Pseudomonas aeruginosa at pH 72007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1148368Metal chelating activity of the compound assessed as stability constant of metal chelate at 1 to 4.5 x 10'-5 M using Mg2+1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID1148358Metal chelating activity of the compound assessed as metal-compound complex formation using zinc1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID343962Inhibition of 12-O-tetradecanoylphorbol-13-acetate induced EBV-early antigen activation in human Raji cells2008Bioorganic & medicinal chemistry letters, Jul-15, Volume: 18, Issue:14
Correlation between reduction potentials and inhibitions of Epstein-Barr virus activation by anthraquinone derivatives.
AID335922Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of arachidonic acid-stimulated platelet aggregation pretreated 2 mins before arachidonic acid challenge
AID687634Binding affinity to calf thymus DNA at DNA/compound ratio 0.1 to 2 at pH 7 by measuring DNA viscosity2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID336135Antiangiogenic activity against BAEC assessed as inhibition of bFGF-induced cell proliferation after 3 days by MTT assay2002Journal of natural products, Sep, Volume: 65, Issue:9
Bryoanthrathiophene, a new antiangiogenic constituent from the bryozoan Watersipora subtorquata (d'Orbigny, 1852).
AID311291Antibacterial activity against Proteus vulgaris at pH 72007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID687630Binding affinity to calf thymus DNA in Brittone-Robinson buffer at 50 uM at pH 3 by UV-vis spectroscopy2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID466937Inhibition of Trypanosoma cruzi trans-sialidase containing catalytic domain (N58F, R200K) and lectin-like domain (S495 K, V496G, E520K, D593G, I597D, H599R) mutation expressed in Escherichia coli JM109 assessed as MuNANA substrate hydrolysis in presence o2010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID102410Compound was tested for enhancement of proliferation of MCF-7 cell line at a concentration 10 uM2001Bioorganic & medicinal chemistry letters, Jul-23, Volume: 11, Issue:14
Phytoestrogens from the roots of Polygonum cuspidatum (Polygonaceae): structure-requirement of hydroxyanthraquinones for estrogenic activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID311294Antibacterial activity against Escherichia coli at pH 62007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID1440394Antibiofilm activity against Candida albicans CAIF-100 after 24 hrs by Cell-Titer Blue assay2017Journal of medicinal chemistry, 03-23, Volume: 60, Issue:6
Tackling Fungal Resistance by Biofilm Inhibitors.
AID1336376Antagonist activity at SRA in RM1-OVA tumor bearing wild type C57BL/6 mouse derived CD11bpositiveLy6ChighLy6Gnegative myeloid-derived suppressive cells co-cultured with splenocytes assessed as reduction in protein-mediated inhibition of anti CD3/CD28 anti2017Bioorganic & medicinal chemistry letters, 01-01, Volume: 27, Issue:1
Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A.
AID85495Compound was tested for the induction of HaCaT keratinocyte differentiation at 5 uM expressed as the amount of cross-linked protein in cornified envelope assay2001Bioorganic & medicinal chemistry letters, Jan-08, Volume: 11, Issue:1
Heterocyclic substituted anthralin derivatives as inhibitors of keratinocyte growth and inducers of differentiation.
AID285171Activity against planktonic Streptococcus mutans LMG 145582007Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4
In vitro inhibition of Streptococcus mutans biofilm formation on hydroxyapatite by subinhibitory concentrations of anthraquinones.
AID687636Binding affinity to calf thymus DNA assessed as partial intercalation2011European journal of medicinal chemistry, Jul, Volume: 46, Issue:7
DNA-binding study of anthraquinone derivatives using chemometrics methods.
AID85490Induction of Keratinocyte Differentiation in cross-linked envelope assay at 10 uM expressed as difference of the amount of cross-linked protein as a measure of HaCaT keratinocyte differentiation2001Journal of medicinal chemistry, Mar-01, Volume: 44, Issue:5
Antipsoriatic anthrones with modulated redox properties. 5. Potent inhibition of human keratinocyte growth, induction of keratinocyte differentiation, and reduced membrane damage by novel 10-arylacetyl-1,8-dihydroxy-9(10H)-anthracenones.
AID311298Antibacterial activity against Escherichia coli at pH 52007Bioorganic & medicinal chemistry letters, Sep-15, Volume: 17, Issue:18
Synthesis and antibacterial activity of some novel chiral fluorophoric biscyclic macrocycles.
AID336134Antiangiogenic activity against BAEC assessed as inhibition of bFGF-induced cell proliferation in presence of 10% fetal bovine serum after 3 days by MTT assay2002Journal of natural products, Sep, Volume: 65, Issue:9
Bryoanthrathiophene, a new antiangiogenic constituent from the bryozoan Watersipora subtorquata (d'Orbigny, 1852).
AID466939Selectivity for Trypanosoma cruzi trans-sialidase mutant over human Neu22010Bioorganic & medicinal chemistry, Feb-15, Volume: 18, Issue:4
Potent inhibitor scaffold against Trypanosoma cruzi trans-sialidase.
AID683449Toxicity against human HEK293 cells at =<40 uM incubated for 72 hrs by resazurin dye reduction assay2012Journal of natural products, Jun-22, Volume: 75, Issue:6
Albopunctatone, an antiplasmodial anthrone-anthraquinone from the Australian ascidian Didemnum albopunctatum.
AID1148362Metal chelating activity of the compound assessed as stability constant of metal chelate at 1 to 4.5 x 10'-5 M using copper1978Journal of medicinal chemistry, Jan, Volume: 21, Issue:1
Structure and tumor-promoting activity of analogues of anthralin (1,8-dihydroxy-9-anthrone).
AID435887Inhibitory constant against maize casein kinase 2 2003The Journal of biological chemistry, Jan-17, Volume: 278, Issue:3
Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight.
AID335923Antiplatelet activity in rat platelet rich plasma assessed as drug level causing inhibition of ADP-stimulated platelet aggregation pretreated 2 mins before ADP challenge
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1755162Inhibition of acid-mediated aggregation of TTR V30M mutant (unknown origin) expressed in Escherichia coli pretreated for 30 mins at pH 7 followed by protein dilution in acetate buffer and further incubated for 96 hrs at pH 4.6 by thioflavin-T fluorescence2021Bioorganic & medicinal chemistry, 08-15, Volume: 44Inhibitory activities of anthraquinone and xanthone derivatives against transthyretin amyloidogenesis.
AID624606Specific activity of expressed human recombinant UGT1A12000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1796663Kinase Inhibition Assay from Article 10.1074/jbc.M209367200: \\Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight.\\2003The Journal of biological chemistry, Jan-17, Volume: 278, Issue:3
Inhibition of protein kinase CK2 by anthraquinone-related compounds. A structural insight.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2011The Journal of biological chemistry, Jan-21, Volume: 286, Issue:3
Danthron functions as a retinoic X receptor antagonist by stabilizing tetramers of the receptor.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (163)

TimeframeStudies, This Drug (%)All Drugs %
pre-199055 (33.74)18.7374
1990's30 (18.40)18.2507
2000's24 (14.72)29.6817
2010's41 (25.15)24.3611
2020's13 (7.98)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.28

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.28 (24.57)
Research Supply Index5.16 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index44.79 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.28)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (1.17%)5.53%
Reviews7 (4.09%)6.00%
Case Studies6 (3.51%)4.05%
Observational0 (0.00%)0.25%
Other156 (91.23%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]